An intraperitoneal (IP) injection delivers a substance directly into the peritoneal cavity, the fluid-lined space in the abdomen that surrounds the intestines, liver, spleen, and other organs. This route is one of the most common methods of drug administration in laboratory animal research, prized for its speed and simplicity, and it also has a handful of specialized clinical uses in humans, from chemotherapy for abdominal cancers to peritoneal dialysis for kidney failure. The anatomy that makes it work, the technique that keeps it safe, and the surprisingly high rate at which it can go wrong all deserve a closer look.
Why the Peritoneal Cavity Is Useful for Drug Delivery
The peritoneum is a thin membrane made of mesothelial cells sitting on a connective tissue bed laced with blood and lymphatic vessels. It has two parts. The visceral peritoneum wraps around the organs themselves and accounts for roughly 70% of the total peritoneal surface area; it gets its blood from the celiac, superior mesenteric, and inferior mesenteric arteries, and it drains into the portal vein, meaning substances absorbed here pass through the liver before reaching the rest of the body. The parietal peritoneum lines the abdominal wall and makes up the remaining 30%; it drains into the inferior vena cava, so substances absorbed here enter systemic circulation more directly. Total blood flow to the human peritoneum runs somewhere between 60 and 100 mL per minute, which represents about 1–2% of cardiac output.1PubMed Central. Functional vascular anatomy of the peritoneum in health and disease
What this means in practice is that the peritoneal cavity offers a large, well-perfused surface for absorbing drugs. When a solution is injected into the cavity, it contacts a vast area of membrane. Transport happens between the peritoneal cavity and the blood in discrete capillaries distributed through the tissue surrounding the cavity.2Journal of the American Society of Nephrology. Peritoneal transport physiology: insights from basic research Small molecules cross mainly by diffusion through tiny pores between endothelial cells, while water can also move through a specialized channel called aquaporin-1.3PubMed Central. Physiology of peritoneal dialysis; pathophysiology in long-term patients The result is absorption that, for many drugs, is faster than oral dosing and sometimes approaches intravenous speed.
How the Injection Is Performed in Laboratory Animals
IP injection is overwhelmingly an animal research technique. In mice, rats, and other rodents, the procedure is straightforward enough that it can be learned quickly, which is a major reason it became the go-to route in preclinical studies. The animal is restrained (typically held by the scruff so the abdomen is exposed), and a needle is inserted into the lower quadrant of the abdomen, angled to avoid the midline organs. The standard target is the lower left or lower right quadrant, where the risk of hitting the cecum or bladder is lowest.
Needle size and injection volume scale with the animal. Recommended maximums for a single injection site give a sense of the proportions involved:
- Mouse (25 g): up to 0.5 mL (20 mL/kg), using a 21-gauge needle
- Rat (200 g): up to 4 mL (20 mL/kg), using a 21-gauge needle
- Rabbit (3 kg): up to 30 mL (10 mL/kg), using a 20-gauge needle
These volumes are guidelines published by institutional animal care offices, not hard biological limits, but exceeding them raises the risk of discomfort, organ displacement, or peritonitis.4University of Iowa Office of Animal Resources. Substance Administration – Recommended Volumes (Informational Sheet)
The Misinjection Problem
One of the less-discussed realities of IP injection is that it misses its target more often than most researchers assume. Studies based on necropsy findings report misinjection rates of 6–20% in rats and 10–20% in mice. Even with careful technique and experienced hands, the rate in rats rarely drops below about 6%.5ResearchGate. Review of Intraperitoneal Injection of Sodium Pentobarbital as a Method of Euthanasia in Laboratory Rodents That is a substantial floor for a procedure performed millions of times each year worldwide.
When an injection goes astray, the fluid can end up in several wrong places: deposited in abdominal fat, trapped in the abdominal wall muscle, lodged subcutaneously just under the skin, pushed into the retroperitoneal space behind the cavity, or even injected directly into an organ. Each misplacement changes the drug’s absorption profile. Subcutaneous deposition slows absorption dramatically. Fat deposition can create a depot effect where the drug trickles out over hours instead of minutes. An accidental puncture of the gut or bladder can introduce bacteria and cause peritonitis. For studies where consistent dosing matters, these errors introduce variability that goes unnoticed unless the researcher specifically checks for it at necropsy. The implication for published research is uncomfortable: some fraction of animal pharmacology data was generated under conditions where the drug never reached its intended compartment.
Making the Procedure Less Stressful
Restraint and injection are inherently aversive to rodents, and the conventional technique for IP injection, which involves firmly gripping the animal and tilting it head-down, produces measurable stress. Researchers at one lab developed a modified handling method designed to reduce this. Using the modified approach, animals showed less struggling, fewer vocalizations, and lower fecal output during the procedure. Corticosterone levels, a direct measure of stress hormone, were also lower. Perhaps most telling, animals tested with an affective bias task showed that the conventional method induced a negative emotional state compared to the modified technique.6Scientific Reports. Reducing the stress of drug administration: implications for the 3Rs
This matters beyond animal welfare for a practical reason. Stress itself alters physiology, changing hormone levels, immune function, and drug metabolism. An animal that is highly stressed during dosing is not in the same physiological state as a calm one, which means stress from the injection procedure can become a confound in the experiment. Reducing handling stress is not just kinder; it can improve data quality.
How IP Compares to Other Routes of Administration
IP injection sits in an interesting middle ground pharmacokinetically. It is faster than oral dosing but generally slower than intravenous injection, and bioavailability varies considerably depending on the drug. A study comparing midazolam absorption across routes in rats found that peak blood concentrations were reached in under 7 minutes for subcutaneous, IP, and oral routes. But absolute bioavailability differed sharply: about 39% for subcutaneous, roughly 19% for IP, and under 5% for oral.7PubMed. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics For this particular drug, the IP route was significantly better than swallowing it but worse than subcutaneous injection.
Other drugs tell a different story. A pig model comparing glucagon found that IP bioavailability was significantly lower than subcutaneous, with a median difference of about 13 percentage points.8PubMed Central. Pharmacokinetics of glucagon after intravenous, intraperitoneal and subcutaneous administration in a pig model The inconsistency across drugs is the key takeaway. Because the peritoneal cavity has two drainage paths (portal vein and systemic veins), and because drug properties like molecular size and lipophilicity determine which path dominates, you cannot assume the IP route will behave the same way for every compound. Drugs absorbed mainly through the visceral peritoneum face first-pass metabolism in the liver, which can dramatically reduce their systemic availability. This dual drainage is a feature for some applications and a liability for others.
Despite the pharmacokinetic quirks, IP injection remains popular in preclinical research because it is fast, easy to learn, suitable for repeated dosing, and causes less tissue damage than repeated intravenous injections through the tiny tail veins of mice.9PubMed Central. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? Researchers sometimes treat it as interchangeable with intravenous dosing, though, and the pharmacokinetic data suggest that is not a safe assumption.
Heated Chemotherapy for Abdominal Cancers
The most dramatic human clinical use of the IP route is hyperthermic intraperitoneal chemotherapy, or HIPEC. In this procedure, a surgeon first removes as much visible tumor as possible from the abdominal cavity (cytoreductive surgery), then bathes the cavity in heated chemotherapy solution, typically at around 41–42°C, for 60 to 90 minutes before draining and closing. The idea is to deliver a high concentration of drug directly to the surfaces where peritoneal cancers grow, while the heat improves drug penetration and has its own tumor-killing effect.
A landmark trial in patients with advanced ovarian cancer tested whether adding HIPEC to cytoreductive surgery improved outcomes. The results were striking. Median recurrence-free survival went from about 10.7 months with surgery alone to 14.2 months with HIPEC added. Median overall survival rose from roughly 34 months to nearly 46 months. At a median follow-up of 4.7 years, 62% of surgery-only patients had died compared with 50% in the HIPEC group.10PubMed. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer That is a substantial improvement, though it comes with the significant morbidity of extensive abdominal surgery. HIPEC is also used for cancers that spread to the peritoneum from the colon, appendix, and stomach, though the evidence base varies by tumor type.
Peritoneal Dialysis
Peritoneal dialysis (PD) exploits the same membrane anatomy, but for waste removal rather than drug delivery. Patients with kidney failure instill a glucose-rich dialysis solution into the peritoneal cavity through a surgically placed catheter. Waste products like urea and creatinine diffuse from the blood in peritoneal capillaries across the membrane and into the solution, while excess water is pulled out by osmotic pressure. Even diffusion of small solutes across the peritoneal membrane is relatively slow, and only a fraction of the membrane’s surface area actively participates in transport at any given time.11PubMed. Solute transport across the peritoneal membrane This is why PD requires multiple exchanges per day or an overnight automated cycling machine.
Water transport in PD happens through two pathways. Some water follows solutes through the inter-endothelial pores (hydrostatic ultrafiltration), while “free water” moves through aquaporin-1 channels driven by the osmotic gradient of the glucose in the dialysate.3PubMed Central. Physiology of peritoneal dialysis; pathophysiology in long-term patients Over years of PD, the peritoneal membrane can undergo structural changes that alter its transport characteristics, which is one of the major long-term challenges of this therapy.
Intraperitoneal Insulin Delivery
A less well-known human application is intraperitoneal insulin delivery via implantable pumps. In a healthy pancreas, insulin enters the portal vein and reaches the liver at high concentrations before being diluted in the general circulation. Subcutaneous insulin injections, the standard treatment for type 1 diabetes, bypass this portal route entirely, delivering insulin to peripheral tissues and the liver at roughly equal concentrations. Implantable pumps that deliver insulin into the peritoneal cavity exploit the visceral peritoneum’s portal drainage to restore something closer to the natural portal-peripheral insulin gradient.12PubMed Central. Finding the right route for insulin delivery – an overview of implantable pump therapy The liver gets a higher insulin dose, which improves glucose regulation and reduces peripheral hyperinsulinemia. These devices remain niche, partly because of the surgical requirement and partly because of catheter complications, but they represent a clever use of peritoneal anatomy.
Veterinary Uses Beyond the Lab
IP injection is not limited to rodent research; it has practical veterinary applications as well. Dehydrated neonatal calves, for example, sometimes need fluid resuscitation but lack accessible veins for an IV. A study administering 4 liters of isotonic saline into the peritoneal cavity of healthy calves found that the fluid was effectively absorbed into the systemic circulation within a clinically useful timeframe. Measurements of plasma protein, chloride, and sodium changes confirmed systemic absorption, while markers of inflammation showed no evidence of peritonitis from the procedure.13American Journal of Veterinary Research. Intraperitoneal fluid administration to neonatal calves For field veterinarians working without the equipment for IV catheterization, IP fluid therapy offers a viable alternative.
Diagnostic Peritoneal Lavage
Not every use of the peritoneal cavity involves putting drugs in. Diagnostic peritoneal lavage (DPL) is a trauma procedure that instills sterile saline into the cavity and then withdraws it to check for blood or bowel contents, signs that an injury has ruptured an organ. DPL is highly accurate for detecting intraperitoneal hemorrhage or a perforated bowel, but it has been largely displaced by focused abdominal sonography for trauma (FAST) and CT scanning, both of which are noninvasive.14PubMed Central. Diagnostic peritoneal lavage: a review of indications, technique, and interpretation DPL is still taught and occasionally used in settings where imaging is unavailable, such as austere or resource-limited environments, or when a patient is too unstable to leave the trauma bay for a CT scanner.
Emerging Drug Delivery Platforms
Researchers are working to overcome some of the IP route’s limitations, particularly its short drug residence time. A solution injected into the peritoneal cavity is absorbed or redistributed within hours, which is fine for single-dose studies but suboptimal for cancer therapy, where sustained local drug exposure would be more effective. Hydrogel-based systems aim to solve this by encapsulating drugs in a gel matrix that sits in the peritoneal cavity and releases its payload gradually. These platforms can raise local drug concentrations at tumor surfaces while reducing the systemic toxicity that comes from high-dose intravenous chemotherapy.15PubMed Central. Hydrogel-Based intraperitoneal drug delivery platforms for peritoneal metastasis: strategies, advances, and prospects
Beyond hydrogels, the toolkit under investigation includes nanoparticles, microparticle-hydrogel composites, and implantable devices, all designed for sustained, region-specific drug release within the peritoneal cavity.16PubMed. Intraperitoneal drug delivery systems for peritoneal carcinomatosis: Bridging the gap between research and clinical implementation Most of this work is preclinical or in early-phase trials. The gap between a promising nanoparticle formulation in mice and a clinically approved product in humans remains wide, but the direction of research is clear: the peritoneal cavity is being reimagined not just as a space to inject things into, but as a compartment that can be engineered for controlled, long-duration therapy.17PubMed Central. Drug delivery systems for intraperitoneal therapy
When IP Administration Can Cause Harm
The peritoneal cavity is normally a sterile environment, and introducing anything into it carries infection risk. Peritonitis, inflammation of the peritoneum caused by bacterial contamination, is the most feared complication. In peritoneal dialysis patients, peritonitis from contaminated equipment or catheter site infections is a leading cause of treatment failure and switch to hemodialysis. In animal research, peritonitis can result from a misinjection that punctures the gut, releasing intestinal bacteria into the cavity. Even without perforation, non-sterile technique or irritating substances can trigger a sterile inflammatory response.
Adhesion formation is another concern, particularly with repeated IP injections or chemotherapy. The peritoneum responds to injury by forming fibrous bands between organs, which can cause bowel obstruction in severe cases. HIPEC, with its combination of surgical trauma and chemical irritation, carries this risk to a heightened degree, and surgeons weigh the survival benefit against the real possibility of adhesion-related complications months or years later.
In animal studies, the choice of injectable solution matters. Strongly acidic or alkaline solutions, hyperosmolar formulations, and certain solvents can damage the mesothelium directly. Guidelines for IP injection in rodents stress not only sterile technique but also pH and osmolality matching to physiological ranges, since the large, sensitive membrane lining the cavity amplifies the consequences of chemical irritation compared to, say, a subcutaneous injection where the exposed tissue area is much smaller.